AbbVie has announced a licensing deal with Danish company Gubra for its experimental weight loss drug, GUB014295. The agreement includes a $350 million upfront payment and up to $1.9 billion in potential payouts if development and sales milestones are met. This new partnership comes as AbbVie seeks to expand its pipeline following the loss of patent protection for Humira, its best-selling autoimmune treatment.
Source: https://www.statnews.com/2025/03/03/abbvie-gubra-obesity-license-agreement